News Quantified

DBVT – dbv technologies s.a. - american depositary shares (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

DBV Technologies S.A. (NASDAQ: DBVT) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.

Combined General Meeting of May 16, 2024 [Yahoo! Finance]

Combined General Meeting of May 16, 2024

DBV Technologies S.A. (NASDAQ: DBVT) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.

Egg Allergy Drug Pipeline Research 2024 Featuring Aimmune Therapeutics, DBV Technologies, and ASIT Biotech [Yahoo! Finance]

6.5%

MISS

Form ARS DBV Technologies S.A. For: Dec 31

Form DEF 14A DBV Technologies S.A. For: May 16

Form PRE 14A DBV Technologies S.A. For: May 16

Form 4 DBV Technologies S.A. For: Mar 08 Filed by: Tasse Daniel

Form 8-K DBV Technologies S.A. For: Mar 08

Top News Gainers

3/18 DBV TECHNOLOGIE/S (NASDAQ: DBVT) was downgraded by analysts at Bryan, Garnier & Co from a "buy" rating to a "neutral" rating. 27.9%

3/17 Monthly information regarding the total number of voting rights and total number of shares of the Company as of February 29, 2020 and March 4, 2020 25.8%

1/8 DBV Technologies Reports Positive Three-Year, Long-Term Data from the PEOPLE Phase III Open-Label Extension Study of Viaskin Peanut in Children with Peanut Allergy 14.8%

4/21 DBV TECHNOLOGIE/S (NASDAQ: DBVT) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 14.1%

4/14 Form 6-K DBV Technologies S.A. For: Apr 13 13.6%

4/7 DBV TECHNOLOGIE/S (NASDAQ: DBVT) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $4.25 price target on the stock. 10.6%

7/3 DBV TECHNOLOGIE/S (NASDAQ: DBVT) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 10.2%

8/7 DBV Technologies Submits Biologics License Application to U.S. Food and Drug Administration for Viaskin Peanut for the Treatment of Peanut Allergy 9.5%

2/26 DBV TECHNOLOGIE/S (NASDAQ: DBVT) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. 7.7%

4/15 Monthly information regarding the total number of voting rights and total number of shares of the Company 5.8%

Top News Decliners

3/10 DBV TECHNOLOGIE/S (NASDAQ: DBVT) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $9.25 price target on the stock. -14.2%

1/29 Form 6-K DBV Technologies S.A. For: Jan 29 -13.2%

3/12 DBV TECHNOLOGIE/S (NASDAQ: DBVT) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -11.7%

3/20 DBV TECHNOLOGIE/S (NASDAQ: DBVT) was downgraded by analysts at Kepler Capital Markets from a "buy" rating to a "hold" rating. -11.6%

12/20 DBV TECHNOLOGIE/S (NASDAQ: DBVT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $25.00 price target on the stock. -8.7%

2/4 Form 6-K DBV Technologies S.A. For: Feb 04 -8.6%

3/5 DBV TECHNOLOGIE/S (NASDAQ: DBVT) had its "buy" rating re-affirmed by analysts at Stifel Nicolaus. They now have a $18.00 price target on the stock. -8.5%

1/9 Form 6-K DBV Technologies S.A. For: Jan 08 -8.4%

10/9 DBV Technologies Announces Pricing of $125 million (€114 million) Global Offering of Ordinary Shares, Including in the Form of American Depositary Shares -8.2%

4/14 DBV TECHNOLOGIE/S (NASDAQ: DBVT) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $4.75 price target on the stock. -8.2%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day